DiaMedica Therapeutics Inc. (NASDAQ:DMAC) Short Interest Update

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) saw a large decrease in short interest during the month of November. As of November 30th, there was short interest totalling 151,500 shares, a decrease of 12.2% from the November 15th total of 172,500 shares. Based on an average trading volume of 83,100 shares, the short-interest ratio is presently 1.8 days.

DiaMedica Therapeutics Price Performance

Shares of DMAC stock traded down $0.11 on Tuesday, hitting $5.20. The stock had a trading volume of 65,662 shares, compared to its average volume of 58,839. The stock has a market cap of $222.36 million, a price-to-earnings ratio of -9.48 and a beta of 1.51. DiaMedica Therapeutics has a 12-month low of $2.14 and a 12-month high of $5.74. The business has a 50 day moving average of $4.64 and a 200 day moving average of $3.88.

Institutional Trading of DiaMedica Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. grew its stake in DiaMedica Therapeutics by 26.3% in the 1st quarter. Vanguard Group Inc. now owns 1,013,522 shares of the company’s stock valued at $2,807,000 after purchasing an additional 211,351 shares during the period. Geode Capital Management LLC grew its position in DiaMedica Therapeutics by 29.6% during the third quarter. Geode Capital Management LLC now owns 306,958 shares of the company’s stock valued at $1,286,000 after buying an additional 70,070 shares during the period. Blue Trust Inc. purchased a new stake in DiaMedica Therapeutics during the third quarter worth about $185,000. Magnolia Capital Advisors LLC purchased a new stake in DiaMedica Therapeutics during the second quarter worth about $87,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new stake in DiaMedica Therapeutics in the third quarter worth about $40,000. 10.12% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and set a $7.00 price target on shares of DiaMedica Therapeutics in a research note on Friday, November 15th.

About DiaMedica Therapeutics

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.